Antibodies Contribute to Effective Vaccination against Respiratory Infection by Type A Francisella tularensis Strains
- 1 April 2011
- journal article
- Published by American Society for Microbiology in Infection and Immunity
- Vol. 79 (4), 1770-1778
- https://doi.org/10.1128/iai.00605-10
Abstract
Pneumonic tularemia is a life-threatening disease caused by inhalation of the highly infectious intracellular bacterium Francisella tularensis . The most serious form of the disease associated with the type A strains can be prevented in experimental animals through vaccination with the attenuated live vaccine strain (LVS). The protection is largely cell mediated, but the contribution of antibodies remains controversial. We addressed this issue in a series of passive immunization studies in Fischer 344 (F344) rats. Subcutaneous LVS vaccination induced a robust serum antibody response dominated by IgM, IgG2a, and IgG2b antibodies. Prophylactic administration of LVS immune serum or purified immune IgG reduced the severity and duration of disease in naïve rats challenged intratracheally with a lethal dose of the virulent type A strain SCHU S4. The level of resistance increased with the volume of immune serum given, but the maximum survivable SCHU S4 challenge dose was at least 100-fold lower than that shown for LVS-vaccinated rats. Protection correlated with reduced systemic bacterial growth, less severe histopathology in the liver and spleen during the early phase of infection, and bacterial clearance by a T cell-dependent mechanism. Our results suggest that treatment with immune serum limited the sequelae associated with infection, thereby enabling a sterilizing T cell response to develop and resolve the infection. Thus, antibodies induced by LVS vaccination may contribute to the defense of F344 rats against respiratory infection by type A strains of F. tularensis .Keywords
This publication has 40 references indexed in Scilit:
- Safety, reactogenicity and immunogenicity of Francisella tularensis live vaccine strain in humansVaccine, 2009
- Vaccination of Fischer 344 rats against pulmonary infections by Francisella tularensis type A strainsVaccine, 2009
- Oral Live Vaccine Strain-Induced Protective Immunity against PulmonaryFrancisella tularensisChallenge Is Mediated by CD4+T Cells and Antibodies, Including Immunoglobulin AClinical and Vaccine Immunology, 2009
- Establishment of lethal inhalational infection with Francisella tularensis (tularaemia) in the common marmoset (Callithrix jacchus)International Journal of Experimental Pathology, 2009
- Antigen-specific B-1a antibodies induced byFrancisella tularensisLPS provide long-term protection againstF. tularensisLVS challengeProceedings of the National Academy of Sciences of the United States of America, 2009
- Francisella tularensisInfection-Derived Monoclonal Antibodies Provide Detection, Protection, and TherapyClinical and Vaccine Immunology, 2009
- Levofloxacin rescues mice from lethal intra-nasal infections with virulent Francisella tularensis and induces immunity and production of protective antibodyVaccine, 2008
- Cellular and humoral immunity are synergistic in protection against types A and B Francisella tularensisVaccine, 2008
- Diverse Myeloid and Lymphoid Cell Subpopulations Produce Gamma Interferon during Early Innate Immune Responses toFrancisella tularensisLive Vaccine StrainInfection and Immunity, 2008
- Generation and characterization of hybridoma antibodies for immunotherapy of tularemiaImmunology Letters, 2007